Pricing Log in Create free account
Saturday 17 October 2026 Export KRRO’s income statement to Excel — free account

Korro Bio, Inc.

KRRO Healthcare Biotechnology

Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.53 0.78 −8.38%
Market cap
$137.1M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
n/a
Altman Z
−6.75
Beneish M
−3.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 20.79
Total sells 5.70
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — 10 — — — — 1 — —
Sell — — — — — — 2 5 1 4 3 —
Insider Ownership 41.71%

Capital & Financial Ratios $m

Market Cap 137.09
Revenue 6.39
Net Income (106.64)
Free Cash Flow (68.26)
Net Debt (115.04)
Current Ratio 9.55 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.98) (negative: loss-making)
P/S ratio 23.51 (above 10: high)
P/B ratio 1.46
Past 5Y EPS Growth —
This Y EPS Growth 57.40% (at or above 15%: strong)
Next Y EPS Growth 8.16%
Next Y revenue growth (94.13%) (below 0%: weak)
Next 5Y EPS Growth 30.71% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 8.4×, against a ten-year median of 3.3×; over the ten years it ranged from −2.1× in 2024 to 37.4× in 2021.
P/S against its own 10 years 86.10%
10-year low 10-year high
P/B against its own 10 years 49.30%
10-year low 10-year high
EV/Sales against its own 10 years 59.12%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 166 126 75 115
Receivables — 2 1 —
Inventory — — — —
Other 4 — — —
173 132 82 121
2023 2024 2025 Q'26
Payables 7 4 2 4
ST’ Debt — — — —
Other — — — —
19 15 12 13

Compound Annual Growth %

10y 5y 3y
Sales — — (44.30%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (23.20%) (7.42%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 3 1 1 1 6
’24 — — — — 2
’21 5 9 — — 14
’20 7 9 11 10 37
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (17) — — —
’25 (24) (19) (17) (18) (79)
’24 (22) (15) (16) (7) (60)
’23 (20) (15) (12) (21) (67)
’22 (17) (13) (12) (11) (54)
’21 (25) (18) (15) (18) (76)
’20 (9) (10) (11) (15) (45)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (17) — — —
’25 (25) (19) (17) (18) (79)
’24 (28) (21) (21) (9) (78)
’23 (21) (19) (12) (23) (75)
’22 (17) (13) (12) (16) (59)
’21 (26) (20) (15) (18) (79)
’20 (10) (11) (12) (19) (52)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.69) (1.07) — — —
’25 (2.49) (2.74) (1.92) (5.32) (12.48)
’24 (2.44) (2.43) (2.26) (2.26) (9.37)
’23 (72.08) (63.95) (65.11) 148.05 (53.08)
’22 (33.50) (30.50) (27.50) (24.50) (227.58)
’21 (30.00) (26.00) (36.50) (31.00) (123.50)
’20 (8.00) (9.50) (8.00) (15.00) (41.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 558.50 725.00 234.00 50.00 9.15 30.01 5.20

Analyst estimates 2026–2028

Powerpack
High — — — 1,024.50 2,144.55 2,918.50 289.50 279.50 98.00 55.89
People
People Employees — — 39 47 87 74 48 101 104 58
Revenue/emp, $m — — 0.00 0.62 0.43 0.19 0.00 0.00 0.02 0.11
Income, $m
Income, $m Revenue — — — 29 37 14 — — 2 6
Gross margin, % — 0.00 0.00 100.00 100.00 100.00 0.00 — 100.00 100.00
EBT — (20) (19) (19) (26) (85) (58) (81) (83) (117)
EBT margin, % — 0.00 0.00 (64.76) (71.59) (601.87) 0.00 0.00 (3,674.15) (1,824.52)
Net income — (20) (19) (19) (27) (85) (58) (81) (84) (117)
Depreciation — 1 1 1 1 3 2 4 2 4
Per share, $
Per share, $ Revenue — 0.00 0.00 167.32 57.33 20.48 0.00 0.00 0.25 0.68
Earnings — (1,439.33) (626.41) (114.50) (41.00) (123.50) (227.58) (53.08) (9.37) (12.48)
Cash flow — (1,036.45) (556.34) 197.78 (70.05) (110.71) (210.37) (44.00) (6.73) (8.36)
Capex — (132.13) (14.25) (6.15) (10.34) (4.24) (20.14) (5.12) (2.01) (0.06)
Free cash flow — (1,168.58) (570.59) 191.63 (80.39) (114.95) (230.51) (49.13) (8.74) (8.42)
Book value — 0.00 1,321.11 967.39 298.39 190.43 254.24 111.13 17.98 5.48
Shares, m — 0 0 0 1 1 0 2 9 9
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 — — 0.00 0.00
P/S — — — 0.00 30.75 5.00 — — 9.63 11.77
P/B — — — 0.91 5.91 1.35 — — 2.12 1.46
EV/Sales — — — 0.00 25.21 1.72 — — 6.57 2.88
EV/FCF — — — (1.98) (17.98) (0.77) — — (2.97) (0.23)
Cash, $m
Cash, $m Operating cash flow — (15) (17) 34 (45) (76) (54) (67) (60) (79)
Capex — (2) 0 (1) (7) (3) (5) (8) (18) (1)
Free cash flow — (16) (17) 33 (52) (79) (59) (75) (78) (79)
Balance, $m
Balance, $m Working capital — 16 39 169 198 123 48 153 117 70
Total debt — 47 85 — 15 15 14 — — —
Net debt — 29 43 (217) (205) (116) (55) (166) (126) (75)
Shareholders’ equity — — 40 167 192 131 65 170 160 51
Returns, %
Returns, % ROA — (90.85) (86.06) (14.79) (10.87) (37.63) (44.80) (54.96) (37.32) (69.03)
ROIC — (35.44) (14.24) 0.00 0.00 (347.42) (384.74) (1,404.78) (167.38) 0.00
ROE — 54.58 51.70 (32.23) (14.73) (52.39) (365.06) (229.04) (50.61) (110.70)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Korro Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MOLN Molecular Partners AG Sponsored ADR $143.5M — (loss-making) — (loss-making) −98.86% (below 0%: shrinking) n/m +23.77% (above 0%: growing) 0.00% 0.00% Compare
TARA Protara Therapeutics, Inc. $141.8M — (loss-making) — — n/m −28.10% (below 0%: shrinking) 0.00% 0.00% Compare
ALXO ALX Oncology Holdings Inc. $138.3M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +31.65% (above 0%: growing) 0.00% 0.00% Compare
NKTX Nkarta, Inc. $138.2M — (loss-making) — — n/m −29.19% (below 0%: shrinking) 0.00% 0.00% Compare
AVXL Anavex Life Sciences Corp. $137.2M — (loss-making) — — n/m +27.02% (above 0%: growing) — 0.00% Compare
KRRO Korro Bio, Inc. $137.1M — (loss-making) — (loss-making) −86.28% (below 0%: shrinking) n/m +12.07% (above 0%: growing) 100.00% 0.00%
ANTX AN2 Therapeutics, Inc. $135.9M — (loss-making) — — n/m +7.91% (above 0%: growing) 0.00% 0.00% Compare
CUE Cue Biopharma, Inc. $135.6M — (loss-making) — (loss-making) +166.66% (above 0%: growing) n/m −742.65% (below 0%: shrinking) 100.00% (1,113.30%) Compare
TLSA Tiziana Life Sciences Ltd $134.7M — (loss-making) — — −258.11% (below 0%: shrinking) +18.03% (above 0%: growing) 0.00% — Compare
Median of peers $137.7M — — −98.86% — +12.97% 0.00% 0.00%

All 614 Biotechnology stocks →

Korro Bio, Inc. (KRRO) key facts

  • Strength: Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.
  • Korro Bio, Inc. (KRRO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, KRRO traded at $8.53, a market capitalization of $137.1 million.
  • Return on equity was −110.7% and debt-to-equity 0.00.
  • Its Altman Z-score is −6.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Korro Bio, Inc. (KRRO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/KRRO · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com